FOXO Technologies (FOXO, Financial) has announced its decision to move forward with the spin-off of its subsidiary, FOXO Labs. This entity specializes in the burgeoning field of epigenetics, focusing on developing biomarkers that integrate into both underwriting frameworks and consumer engagement solutions. FOXO Labs holds Patent No. 11,817,214, which is centered around a machine learning model that assesses biochemical states and medical conditions using DNA epigenetic data.
Significantly, the company's technology promises unprecedented insights into health, lifestyle, and longevity, all derived from a simple saliva sample. By utilizing saliva-based biomarkers, the need for more intrusive procedures like blood or urine collection is eliminated. This innovation not only simplifies the process for consumers but also advances scientific research by offering sophisticated epigenetic testing and bioinformatics tools.
